This site is intended for healthcare professionals
A new era for epidermolysis bullosa at EADV 2023

A new era for epidermolysis bullosa at EADV 2023

Amryt Pharmaceuticals sponsored
Read time: 60 mins
Last updated: 15th Feb 2024
Published:15th Feb 2024

At the European Academy of Dermatology and Venereology (EADV) Congress 2023, epidermolysis bullosa (EB) experts discussed investigational treatments for EB and experience in practice with currently approved treatments in an Industry Expert Hub session sponsored by Amryt Pharmaceuticals

The session was chaired by Professor Cristina Has and featured presentations from Dr Alexander Nyström and Dr Su Lwin on preclinical models and pathophysiology of EB, wound healing, and translating research into investigational therapies. In the second half, Professor Christine Bodemer and Dr Mauricio Torres explored real-world experience and what the latest data could mean for people living with EB.

Meet the experts


Professor Cristina Has.png

Professor Cristina Has

Cristina Has, MD, is Professor at the Department of Dermatology, University of Freiburg, Germany. Her research focuses on EB and other genetic skin disorders. Her clinical activity includes general and paediatric dermatology and genodermatoses. 

Disclosures: Professor Has has consulted for Amryt Pharmaceuticals, Desitin, Krystal, and Novartis.


Dr Alexander Nystro╠łm.png

Dr Alexander Nyström

Alexander Nyström, PhD, is group leader at the Department of Dermatology, University of Freiburg, Germany. His translational research focuses on the biology of the dermal extracellular matrix in genetic skin fragility disorders and acquired wound healing pathologies.

Disclosures: Dr Nyström has consulted for Amryt Pharmaceuticals.


Dr Su Lwin.png

Dr Su Lwin

Su Mar Lwin, PhD, MRCP, is a Dermatology Resident and Honorary Lecturer at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, King’s College London, UK. Lwin has a PhD in stem cells and regenerative medicine and has dedicated her research to the development and clinical application of gene and cell therapies for EB. She is co-founder of the Burma Skincare Initiative, a UK-registered global health charity with a focus on Myanmar (Burma).

Disclosures: Dr Lwin has consulted for Amryt Pharmaceuticals and Janssen.


Professor Christine Bodemer.png

Professor Christine Bodemer

Christine Bodemer, MD, PhD, is Head of the Department of Dermatology, Necker Enfants-Malades Hospital in Paris, France, and Professor of Dermatology at the Paris Descartes – Paris Sorbonne University. She particularly specialises in paediatric dermatology. One of her main areas of interest is rare skin diseases in children, and she coordinates a national expert centre (MAGEC), the French national network (FIMARAD) and the European network (ERN-SKIN) on rare diseases of the skin. Bodemer has been President-Elect of the French Society of Pediatric Dermatology (2011–2016) and secretary-elect of the European Society of Pediatric Dermatology (2016–2018). She is currently a member of the board of directors of the International Society of Pediatric Dermatology.

Disclosures: Professor Bodemer has consulted for Amryt Pharmaceuticals, Boehringer Ingelheim, Krystal, Novartis, Pfizer, and Sanofi.

Professor Mauricio Torres.png

Dr Mauricio Torres

Mauricio Torres is a paediatric dermatologist and chief of the dermatology residency programme at the Fundación Universitaria de Ciencias de la Salud, Hospital de San José and Hospital Infantil Universitario de San José in Bogota, Colombia. His research focuses on EB, vascular tumours, psoriasis and atopic dermatitis. Dr Torres is Vice President of the Colombian Association of Pediatric Dermatology (ACDP).

Disclosures: Dr Torres has consulted for AbbVie, Amryt Pharmaceuticals, Avicanna, Carnot/Panalab, Galderma, Gencell Pharma, Isdin, Janssen, La Roche-Posay, Novartis, Pfizer, Pierre Fabre, Roemmers, Sanofi, and Uno Healthcare.


This content has been developed by EPG Health, for Medthority, in collaboration with Amryt Pharmaceuticals, the sponsor of the Industry Expert Hubs held at the European Academy of Dermatology and Venereology Congress in October 2023. This content is intended for healthcare professionals only. Amryt Pharmaceuticals is a wholly owned subsidiary of CHIESI SpA and the marketing authorisation holder for Oleogel-S10 in the EU and UK.

Job bag code: VV-MED-02197

DOP: February 2024